Implications
of Staging for Survival Rates |
page
65 |
CLINICAL
STAGE
|
|
|
Fig.
62: Cumulative
proportion of patients
with non-small cell lung
cancer expected to survive
5 years after treatment
according to clinical
stage of disease. cStage
IA, n=675; cIB, n=1,130;
cIIA, n=26; cIIB, n=329;
cIIIA, n=445; cIIIB,
n=836; cIV, n=1,166.
P < 0.05: Pairwise
comparisons: cIA vs cIB,
P <0.05; cIB vs cIIA, >0.05;
cIIA vs cIIB, P < 0.05;
cIIB vs cIIIA, P < 0.05;
cIIIA vs cIIIB, P< 0.05;
cIIIB vs cIV, P <0.05. |
|
|
|
|
|
|
|
|
|
|
|
|